United Kingdom (UK)
Recombinant monoclonal antibody to PSMA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 7F12.
UniProt Accession Number of Target Protein: Q04609
Alternative Name(s) of Target: PSM; FOLH1; FOLH; FGCP; GCPII; mGCP; NAALAD1; GIG27; Prostate specific membrane antigen; Glutamate carboxypeptidase 2; Cell growth-inhibiting gene 27 protein; Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; Glutamate carboxypeptidase II; Membrane glutamate carboxypeptidase; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; Prostate-specific membrane antigen; Pteroylpoly-gamma-glutamate carboxypeptidase
Immunogen: The original antibody was generated by immunizing mice with cell membranes and purified PSMA protein isolated from LNCaP cells.
Specificity: This antibody binds a conformational epitope on the human PSMA. This antibody can bind native PSMA protein but were unreactive with any fusion protein containing a portion of the PSMA sequence. Heat denaturation of PSMA also results in loss of binding.
Application Notes: This antibody was capable of detecting membrane fractions from human prostatic adenocarcinoma LNCaP and PC3 cells in a solid phase ELISA. This antibody was used for immunoprecipitation of PSMA from LNCaP cell detergent lysates. Antibody binding competition assays were done using flow cytometry and it revealed that 7F12 binds an epitope closed to another murine anti-PSMA antibody 3C6. This antibody was shown to mediated antibody dependent cellular cytotoxicity in human prostatic adenocarcinoma LNCaP cell targets with PBMC's from two donors (WO2003064606). This antibody was also used in the treatment of in vivo tumor xenografts with a combination of Taxotere® (US20090297438).
Antibody first published in: Deo et al. Human monoclonal antibodies to prostate specific membrane antigen (PSMA). WO2003064606 PMID: